AI assistant
Sending…
ADMA BIOLOGICS, INC. — Director's Dealing 2021
Mar 2, 2021
31261_dirs_2021-03-01_bfbf8a17-c2e8-49a2-8322-80a22b2315a2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ADMA BIOLOGICS, INC. (ADMA)
CIK: 0001368514
Period of Report: 2021-02-25
Reporting Person: ELMS STEVE (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-25 | Stock Option (right to buy) | $2.35 | A | 55000 | Acquired | 2031-02-25 | Common Stock (55000) | Direct |
Footnotes
F1: The options vest in twelve equal monthly installments, becoming fully vested on February 25, 2022.
More from ADMA BIOLOGICS, INC.
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 4
Annual Report
2026
Apr 15
Proxy Solicitation & Information Statement
2026
Apr 15
Regulatory Filings
2026
Mar 27
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Mar 2